Drug Profile

DPX 101

Alternative Names: DPX-101

Latest Information Update: 12 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Damona Pharmaceuticals
Class Antipsychotics; Nootropics; Small molecules
Mechanism of Action GABA A alpha 5 receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cognition disorders; Schizophrenia

Most Recent Events

04 Feb 2025 Updated pharmacodynamics data from a preclinical trial in Cognition disorders released by Damona Pharmaceuticals
04 Feb 2025 Damona Pharmaceuticals plans to initiate a phase I trial for Cognitive Deficits in Alzheimer's Disease in first half of 2025
04 Nov 2024 Preclinical trials in Cognition disorders in Canada (PO) before November 2024 (Damona Pharmaceuticals pipeline, November 2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com